ClinicalTrials.gg
RecruitingNCT07569887APEMMAV-NRUpdated Jul 7, 2026

Exploratory Study of Cerebral Perfusion and Metabolic Alterations and Neurocognitive Disorders in Patients With Unruptured Arteriovenous Malformations Before and After Surgical Treatment

An interventional study of 18F-FDG PET imaging and Neuropsychological Assessment in Unruptured Brain Arteriovenous Malformation, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Arteriovenous Malformations with a site in France — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Malformations · France.

Started
2026
the only one that year
No phase
5 of 15
2 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
University Hospital, Montpellier

Among the 15 studies in Arteriovenous Malformations with a site in France, this one is the only one that started in 2026, is one of 5 with no phase, and was the 15th registered.

Arteriovenous Malformations

92 studies on the registry are indexed under Arteriovenous Malformations; 29 are open to participants now.

Browse Arteriovenous Malformations studies →

Open to participants now

6 of the 15 studies in Arteriovenous Malformations with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 19 Arteriovenous Malformations studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Arteriovenous Malformations with a site in France, or all of them as a file.
02

Study summary

The goal of the clinical trial is to describe perfusion and metabolic alterations in different brain regions before and six months after surgical treatment of arteriovenous malformations in adult patients with unruptured arteriovenous malformations.

Read the detailed description

Unruptured cerebral arteriovenous malformations are a potentially life-threatening condition and the third leading cause of intracerebral hemorrhage in young adults. Approximately two-thirds of patients with arteriovenous malformations experience a rupture leading to intracranial haemorrhage or develop progressive neurological symptoms or deficits. To date, decisions regarding interventional treatment of unruptured arteriovenous malformations are based on the characteristics of the arteriovenous malformation (size, location, etc.).However, the treatment of these arteriovenous malformations remains controversial in the literature, as the morbidity and mortality associated with intervention may exceed those the malformation's natural history. Furthermore, characteristics of arteriovenous malformations observed during examinations (size, hemodynamic patterns, vascular components) are often insufficient to predict spontaneous evolution, haemorrhagic risk, and associated symptoms.

Studies suggest that neurological symptoms may be linked to impaired cerebral perfusion and metabolism, particularly through hypoperfusion in the peri-arteriovenous malformation region or peri-lesional oedema. However, the results of these previous studies remain limited and of little significance.

The proposed project aims to establish a cohort over a 16-month period in order to study in detail the metabolic and perfusion alterations associated with arteriovenous malformations, as well as their neurocognitive and psychological impacts, with the aim of improving the pathophysiology understanding and treatment of these malformations.

03

Conditions studied

  • Unruptured Brain Arteriovenous Malformation

Keywords

  • Arteriovenous malformation
  • Perfusion disorders
  • Metabolism
  • Positon Emission Tomography
  • Neuropathology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 and older
  • Admitted for an unruptured arteriovenous malformation with a decision to proceed with surgery

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse surgical treatment for arteriovenous malformation
  • to 18F-FDG PET (uncontrolled diabete)
  • Patients' inability to lie still for 40 minutes
  • Patients with a confirmed diagnosis of neurodegenerative or psychiatric disorders
  • Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code)
  • Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code)
  • Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code)
  • Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code)
  • Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code)
  • Failure to obtain written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    Radiation: 18F-FDG PET imaging · Other: Neuropsychological Assessment

Interventions

  • Radiation18F-FDG PET imaging

    For the 18F-FDG (fluorodeoxyglucose labelled with fluorine-18) PET scan, a dynamic protocol with the radiopharmaceutical injected directly under the scanner. The dose injected will be the same as that used in routine clinical practice, i.e. calculated based on the patient's weight. The patient must fast for 6 hours prior to the examination. The total duration of the dynamic PET scan is estimated at approximately 1 hour 30 minutes.

  • OtherNeuropsychological Assessment

    For the neuropsychological assessment, a series of standardised tests, validated for the assessment of cognitive functions, will be administered. This assessment will be carried out by neuropsychologists trained in the use of these tests and who administer them as part of their routine practice, or by a trained physiatrist specialising in disorders of the central nervous system. The neuropsychological assessment is expected to take 2 to 3 hours per visit for the patient.

06

What researchers measure

Primary outcomes

  1. Change in Standardized Uptake Value (SUV)

    Changes in Standardized Uptake Value (SUV) measured by 18F-FDG positron emission tomography (PET) in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere)

    Time frame: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

  2. Change in K1 Transfer Constant

    Change in the K1 transfer constant, representing the transfer of the tracer from the plasma compartment to the tissue compartment, measured by 18F-FDG positron emission tomography (PET) measured in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere). Unit : mL.g-1.min-1

    Time frame: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

  3. Change in Ki Net Influx Rate Constant

    Change in Ki net influx rate constant measured by 18F-FDG positron emission tomography (PET) in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere). Unit : mL.g-1.min-1

    Time frame: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

  4. Change in Cerebral Metabolic Rate of glucose (CMRglu)

    Change in cerebral metabolic rate of glucose (CMRglu) measured by 18F-FDG positron emission tomography (PET) in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere). Unit : µmol.100g-¹.min-¹

    Time frame: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

Secondary outcomes

  1. Headache impact

    Headache impact assessed by the total score on the Headache Impact Test - 6 items (HIT-6) Total score between 36 and 78. A higher score indicates a greater functional impact.

    Time frame: Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation

  2. Visual attention and processing speed

    Visual attention and processing speed assessed by completion time on the Trail Making Test - Part A (TMT-A)

    Time frame: Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation

  3. Cognitive flexibility and executive control

    Cognitive flexibility and executive control assessed by completion time on the Trail Making Test - Part B (TMT-B)

    Time frame: Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation

  4. Inhibition and selective attention

    Inhibition and selective attention assessed by completion times and number of errors on the Stroop Test

    Time frame: Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation

  5. Working memory

    Working memory assessed by scores on the Digit Span subtest of the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV)

    Time frame: Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation

  6. Global verbal episodic memory

    Global verbal episodic memory assessed by scores on the 16-item Free Recall / Cued Recall test (RL/RI-16)

    Time frame: Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation

  7. Phonemic and semantic verbal fluency

    Phonemic and semantic verbal fluency assessed by the number of words produced on verbal fluency tests

    Time frame: Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation

  8. Ecological executive functioning

    Ecological executive functioning assessed by raw scores and composite indices on the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A)

    Time frame: Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation

  9. Visual constructive abilities and visual memory

    Visual constructive abilities and visual memory assessed by scores on the Rey-Osterrieth Complex Figure Test

    Time frame: Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation

  10. Visual attention and spatial exploration

    Visual attention and spatial exploration assessed by the number of crossed-out targets, omissions, and their spatial distribution in the Bell Test.

    Time frame: Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

Of 15 interventional studies with no phase under Arteriovenous Malformations, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 77. This study's planned 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 6, 2026
StartActual
Jun 16, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07569887
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Jun 16, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 7, 2026

Study contacts

Lucas RIBEIRO, Dr
Contact
l-ribeiro@chu-montpellier.fr
0467337432 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion